胰高血糖素样肽-1受体激动剂暴露对ICU患者胃肠道结局的影响:多中心匹配队列研究
该多中心回顾性队列研究纳入2018年1月1日至2023年12月31日Mayo Clinic Health System学术与社区医院收治的内科ICU重症患者,比较入院前30天内活跃处方暴露于GLP-1RA者与未暴露者的胃肠道并发症及住院结局。在1:1匹配的1262例患者中,两组恶心/呕吐、便秘、肠梗阻、梗阻、嵌顿或吸入性肺炎的 odds 均无显著差异,ICU与住院死亡率相当。GLP-1RA暴露组住院无事件天数显著更多(估计值1.19;95%CI 0.38–2.0;p=0.004)。作者认为GLP-1RA暴露与非外科重症患者临床显著胃肠道并发症风险增加无关,住院无事件天数增加需进一步研究。
要点
- 在1262例匹配的非外科重症患者中,GLP-1RA暴露组与未暴露组的恶心/呕吐、便秘、肠梗阻、梗阻、嵌顿、吸入性肺炎 odds 均无显著差异。
- GLP-1RA暴露组与未暴露组的ICU死亡率和住院死亡率相当。
- GLP-1RA暴露组住院无事件天数显著多于未暴露组(估计值1.19;95%CI 0.38–2.0;p=0.004)。
- 研究排除了外科ICU患者及入院前30天内无活跃GLP-1RA处方者,匹配基于人口学因素、影响胃肠动力的因素、总体疾病负担和临床严重程度。
适用人群与场景
- 2018年1月1日至2023年12月31日入住Mayo Clinic Health System学术与社区医院内科ICU的糖尿病或肥胖重症患者。
- 排除入住外科ICU的患者,以及既往暴露于GLP-1RA但入院前30天内无活跃处方者。
研究设计与关键结果
- 多中心回顾性队列研究,共识别31327例糖尿病或肥胖患者,其中631例入院前暴露于GLP-1RA;1:1匹配后队列为1262例,基线变量在两组间分布均衡。
- GLP-1RA暴露组与未暴露组在恶心/呕吐、便秘、肠梗阻、梗阻、嵌顿或吸入性肺炎的 odds 上均无显著差异。
- GLP-1RA暴露组与未暴露组的ICU死亡率和住院死亡率相当。
- GLP-1RA暴露组住院无事件天数显著多于未暴露组(估计值1.19;95%CI 0.38–2.0;p=0.004)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:住院无事件天数增加需进一步研究。
对床旁实践的改变
- 作者认为,GLP-1RA暴露与非外科重症患者临床显著胃肠道并发症风险增加无关。
- 作者认为,GLP-1RA暴露患者住院无事件天数增加需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients admitted to the ICU often experience gastrointestinal complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become increasingly prevalent in the treatment of type 2 diabetes mellitus and obesity, and there is evidence that their use may be associated with an increased risk of clinically significant gastrointestinal events. However, their impact on critically ill patients admitted to the medical ICU is unknown.
OBJECTIVES: This study examined whether pre-ICU use of GLP-1RAs was associated with increased incidence of gastrointestinal complications and hospitalization outcomes.
DESIGN, SETTING AND PARTICIPANTS: Multicenter, retrospective cohort study of critically ill patients admitted to academic and community hospitals of Mayo Clinic Health System from January 1, 2018, to December 31, 2023. Patients who were admitted to surgical ICUs and those who were exposed to GLP-1RA medications before but did not have an active prescription within 30 days of admission were excluded. Patients exposed to GLP-1RA were matched with those nonexposed in a 1:1 fashion based on demographic factors, factors affecting gastrointestinal motility, overall illness burden, and clinical acuity.
MAIN OUTCOMES AND MEASURES: Outcomes of interest were the development of gastrointestinal dysfunction, ICU- and hospital-free days, and mortality.
RESULTS: A total of 31,327 patients with diabetes or obesity were identified of whom these, 631 were exposed to GLP-1RA before admission. In the matched cohort of 1262 patients, baseline variables were evenly distributed between the two groups. There were no significant differences in the odds of developing nausea/vomiting, constipation, ileus, obstruction, impaction, or aspiration pneumonia between the GLP-1RA exposed and unexposed groups. Similarly, ICU and hospital mortality rates were comparable across the two groups. However, GLP-1RA exposed patients had significantly more hospital-free days compared with unexposed patients (estimate, 1.19; 95% CI, 0.38-2.0; p = 0.004).
CONCLUSIONS AND RELEVANCE: GLP-1RA exposure was not associated with increased odds of clinically significant gastrointestinal complications in nonsurgical critically ill patients. Increased hospital-free days observed among GLP-1RA exposed patients requires further study.
参考来源
- Gmehlin CG, Nemet M, Rizwan ZM, et al. Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study. Crit Care Explor. 2025. PMID: 40366278. doi:10.1097/CCE.0000000000001263
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。